Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten
✍ Scribed by Emmanuel Gautherot; Jamila Bouhou; Jean-Marc Le Doussal; Corine Manetti; Marie Martin; Eric Rouvier; Jacques Barbet
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 147 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
METHODS.
Nude mice grafted with LS174T human colorectal carcinoma were Epalinges, Switzerland. treated either with 111 megabecquerels (MBq) of iodine-131 labeled bivalent diethylenetriamine pentaacetic acid (DTPA) hapten 20 hours after pretargeting by anti-CEA 1 anti-DTPA-indium bispecific antibody or 12 MBq of iodine-131 labeled anti-CEA IgG.
RESULTS.
Treatment with the IgG induced only a growth delay of 53 { 5 days but all tumors progressed. Treatment with the AES was highly efficient because tumor growth inhibition was achieved over 150 days. Hematologic and overall toxicity of both treatments were equivalent.
CONCLUSIONS. The long term tumor regression consecutive to AES RIT represents
a very significant improvement over the use of directly labeled IgG. Toxicity consecutive to AES or IgG RIT were similar despite an administered activity nearly ten times higher with the AES. However, given the efficacy of the AES treatment, a lower dose may afford lower toxicity and significant antitumor effect.